51 results
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
with motixafortide, the study’s independent DMC issued a recommendation to us that patient enrollment may be ceased immediately, without the need to recruit … factors can delay the commencement and rate of completion of clinical trials, including the inability to recruit patients at the expected rate
6-K
EX-99
BLRX
Bioline Rx Ltd
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
the need to recruit all 177 patients originally planned for the study. In accordance with the DMC’s recommendation, study enrollment was completed
6-K
EX-99
BLRX
Bioline Rx Ltd
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
a recommendation to us that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
a recommendation to us that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study
6-K
EX-99
e91 0xvjy293u7
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
424B5
rxcuiu5 hlp
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
h1xn6o35
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
h8c7h2qio hjk
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
bop rn6rq34do4mwmbkd
18 Nov 21
BioLineRx Reports Third Quarter 2021 Financial Results
7:16am
6-K
EX-99
ycuryamgscy
18 Aug 21
BioLineRx Reports Second Quarter 2021 Financial Results
7:01am
6-K
EX-99
nx7 c0lbzrb
26 May 21
BioLineRx Reports First Quarter 2021 Financial Results
7:54am
424B5
60cecacbd4xrjj107
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
3ar5p41rdymf25z17et
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
0qn kvpipr3uu2hp
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
ofy0t4oj2h5xprf
31 Dec 20
Prospectus supplement for primary offering
4:31pm
6-K
EX-99
jcgv3itduqd 02ka0lt
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
424B5
h1ktz
13 Nov 20
Prospectus supplement for primary offering
4:31pm